Switzerland launches the SwissChips initiative to strengthen the domestic semiconductor industry
The SwissChips initiative aims to bolster the nation’s semiconductor industry by enhancing research and innovation in semiconductor technologies, microelectronics, and integrated circuit design. This move seeks to secure Switzerland’s digital sovereignty and competitive edge amid growing production efforts abroad and limited access to European research infrastructure. With a collaborative investment of CHF 41.6 million from various Swiss institutions, the initiative focuses on creating a robust network for semiconductor R&D, ensuring Switzerland’s technological independence and leadership in the global semiconductor arena.Haut du formulaire
GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments
GeNeuro has raised EUR 5 million through a capital increase to further its research into treatments for neurodegenerative and autoimmune diseases, including the aftereffects of COVID-19. This funding will support the completion of a Phase 2 study in post-COVID conditions. The Geneva-based biopharmaceutical company is known for its innovative work leveraging HERV biology. The investment, facilitated through a mix of private placements and public offerings, will extend GeNeuro’s financial reach into the third quarter of 2024, focusing on developing personalized therapies for patients affected by pathogenic proteins.
Sitem Startup Club, where medtech start-ups thrive in Bern
The Sitem Startup Club in Bern is dedicated to establishing the city as a premier hub for medtech startups in Switzerland and beyond. Launched in 2020, it provides an ecosystem of support, resources, and expertise to help start-ups overcome challenges in investment, regulation, and partnership. Its offerings include the MedTech Booster Program and the Sitem MedTech HUB coworking space, designed to accelerate the growth of early-stage companies in the medtech and adjacent sectors.
Fintech YouHodler secures key registration with Bank of Spain
YouHodler, a Lausanne-based fintech platform specializing in Web3 financial services, has secured its Virtual Asset Service Provider (VASP) registration from the Bank of Spain. This milestone allows YouHodler to offer its services in Spain, complying with the country’s AML and CTF regulations. This development is significant for YouHodler’s expansion in the EU, particularly with the upcoming Markets in Crypto-Assets (MiCA) regulation, reinforcing its commitment to bridge traditional and Web3 finance while adhering to compliance and security standards.
Eyeware’s innovative eye-tracking technology set to enhance the gaming experience
Eyeware, a Valais-based Idiap spin-off, is transforming the gaming experience with its innovative eye-tracking technology. Using computer vision algorithms, Eyeware’s system enables gamers to interact with their devices through gaze control, enhancing immersion in video games and streamlining interactions on Windows PCs. The “Beam Eye Tracker” technology, which converts webcams into head and eye trackers, is compatible with over 200 PC games and available for purchase or subscription.
Infrastructure and Education (Agri&Food in the Canton of Fribourg 5/11)
The “Infrastructure and Education” episode of the “Agri&Food in the Canton of Fribourg” video series, led by Jerry Krattiger of the Fribourg Development Agency, showcases Fribourg’s commitment to agrifood innovation through its educational and research infrastructure. It highlights the University of Fribourg’s chemistry department, the ChemTech lab at the University of Applied Sciences, the dual training system at Grangeneuve, and the relocation of Agroscope to Fribourg.
CSEM and ClexBio unveil groundbreaking bioreactor to advance cardiovascular treatment
CSEM and ClexBio have created a groundbreaking bioreactor to cultivate human veins in the lab, aiming to treat chronic venous insufficiency with bio-engineered vein implants. This collaboration combines ClexBio’s regenerative medicine and hydrogel expertise with CSEM’s automation skills to produce functional, immune-response-free vein grafts. The “Supervene” project promises a shift towards automated regenerative medicine production, with plans for further pre-clinical and human trials, potentially revolutionizing surgery and tissue treatment.
